Payment overview · 2025
General Payments
$134,324.12
53 reported records · 8 companies
Healthcare provider profile · identity verified
Michael J Langworthy, MD
Allopathic & Osteopathic Physicians|Orthopaedic Surgery · NORTH DARTMOUTH, MA · NPI 1841301546
Verified facts
What the public records show
CMS Open Payments records show Michael J Langworthy, MD received $134,324.12 in general payments during 2025 across 53 reported records.
ORTHO DEVELOPMENT CORPORATION accounted for 64.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ORTHO DEVELOPMENT CORPORATION | Unresolved — no canonical attribution shown | $86,673.77 | 64.5% | 23 | 2025 |
| UOC USA INC | Unresolved — no canonical attribution shown | $26,146.72 | 19.5% | 12 | 2025 |
| Heron Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20,665.39 | 15.4% | 9 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $531.89 | 0.4% | 5 | 2025 |
| Ortho Development Corporation | Unresolved — no canonical attribution shown | $91.89 | 0.1% | 1 | 2025 |
| ORTHALIGN INC | Unresolved — no canonical attribution shown | $88.19 | 0.1% | 1 | 2025 |
| Pacira Pharmaceuticals Incorporated | Unresolved — no canonical attribution shown | $63.20 | 0.1% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $63.07 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Royalty or License | $85,427.56 | 13 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $18,150.00 | 3 |
| Consulting Fee | $15,075.00 | 1 |
| Travel and Lodging | $13,027.90 | 8 |
| Food and Beverage | $2,643.66 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Balanced Knee System Normalized: balanced knee system |
Device | ORTHO DEVELOPMENT CORPORATION | $85,520.97 | 14 | 2025 |
Source payment records
|
|||||
| ZYNRELEF Normalized: zynrelef |
Drug | Heron Therapeutics, Inc. | $20,592.04 | 8 | 2025 |
Source payment records
|
|||||
| U-Star II Normalized: u star ii |
Device | UOC USA INC | $15,075.00 | 1 | 2025 |
Source payment records
|
|||||
| UTS, Conformity, U-MII, U2 Revision Stem, PSA, USTAR, U2 Knee Normalized: uts conformity u mii u2 revision stem psa ustar u2 knee |
Device | UOC USA INC | $10,455.88 | 5 | 2025 |
Source payment records
|
|||||
| APONVIE Normalized: aponvie |
Drug | Heron Therapeutics, Inc. | $8,905.25 | 3 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $531.89 | 5 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $531.89 | 5 | 2025 |
Source payment records
|
|||||
| Ovation Hip Stem Normalized: ovation hip stem |
Device | ORTHO DEVELOPMENT CORPORATION, Ortho Development Corporation | $453.70 | 5 | 2025 |
Source payment records
|
|||||
| Balanced Knee Revision System Normalized: balanced knee revision system |
Device | ORTHO DEVELOPMENT CORPORATION | $406.31 | 4 | 2025 |
Source payment records
|
|||||
| Trivicta Normalized: trivicta |
Device | ORTHO DEVELOPMENT CORPORATION | $237.40 | 3 | 2025 |
Source payment records
|
|||||
| USTAR II Normalized: ustar ii |
Device | UOC USA INC | $206.34 | 2 | 2025 |
Source payment records
|
|||||
| U-Star, Conformity, U2 Normalized: u star conformity u2 |
Device | UOC USA INC | $187.76 | 1 | 2025 |
Source payment records
|
|||||
| Legend Normalized: legend |
Device | ORTHO DEVELOPMENT CORPORATION | $125.28 | 2 | 2025 |
Source payment records
|
|||||
| Conformity, U-Motion II, U-STAR II, U2 Normalized: conformity u motion ii u star ii u2 |
Device | UOC USA INC | $120.00 | 2 | 2025 |
Source payment records
|
|||||
| U-STAR II, U2 PF+ Normalized: u star ii u2 pf |
Device | UOC USA INC | $101.74 | 1 | 2025 |
Source payment records
|
|||||
| BKS Uni Normalized: bks uni |
Device | ORTHO DEVELOPMENT CORPORATION | $96.32 | 1 | 2025 |
Source payment records
|
|||||
| Balance Knee Revision System Normalized: balance knee revision system |
Device | ORTHO DEVELOPMENT CORPORATION | $93.41 | 1 | 2025 |
Source payment records
|
|||||
| ORTHALIGN PLUS Normalized: orthalign plus |
Device | ORTHALIGN INC | $88.19 | 1 | 2025 |
Source payment records
|
|||||
| Exparel Normalized: exparel |
Drug | Pacira Pharmaceuticals Incorporated | $63.20 | 1 | 2025 |
Source payment records
|
|||||
| Iovera Normalized: iovera |
Device | Pacira Pharmaceuticals Incorporated | $63.20 | 1 | 2025 |
Source payment records
|
|||||
| TRIATHLON Normalized: triathlon |
Device | Stryker Corporation | $63.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Meloxicam | Meloxicam | 269 | 122 |
| Oxycodone Hcl | Oxycodone Hcl | 42 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | 31 |
| Tramadol Hcl | Tramadol Hcl | 24 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $134,324.12 · 53 records | ORTHO DEVELOPMENT CORPORATION | APONVIE, BKS Uni, Balance Knee Revision System, Balanced Knee Revision System, Balanced Knee System, Conformity, U-Motion II, U-STAR II, U2, Exparel, Iovera, Kerecis GraftGuide, Kerecis SurgiClose, Legend, ORTHALIGN PLUS, Ovation Hip Stem, TRIATHLON, Trivicta, U-STAR II, U2 PF+, U-Star II, U-Star, Conformity, U2, USTAR II, UTS, Conformity, U-MII, U2 Revision Stem, PSA, USTAR, U2 Knee, ZYNRELEF | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error